Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Donor-Derived Viral Specific T-cells (VSTs) — Stella

Home/Allogeneic Stem Cell Transplant/Donor-Derived Viral Specific T-cells (VSTs)

View on ClinicalTrials.gov

Recruiting

Back to Allogeneic Stem Cell Transplant trials

Donor-Derived Viral Specific T-cells (VSTs)

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

Akron Children's Hospital, Akron, Ohio

University of Cincinnati Medical Center, Cincinnati, Ohio

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Key details

Phase

Early testing / Safety & dosing

Sponsor

Children's Hospital Medical Center, Cincinnati

Collaborators

Hoxworth Blood Center

Enrollment target

~750 participants

Started

February 2014

Primary completion

January 2027

Age range

4 Weeks and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.